Literature DB >> 28366484

Adverse Reactions to Biologic Therapy.

Sheenal V Patel1, David A Khan2.   

Abstract

Biologic therapies are emerging as a significant therapeutic option for many with debilitating inflammatory and autoimmune conditions. As expansion in the number of FDA-approved agents continue to be seen, more unanticipated adverse reactions are likely to occur. Currently, the diagnostic tools, including skin testing and in vitro testing, to evaluate for immediate hypersensitivity reactions are insufficient. In this review, management strategies for common acute infusion reactions, injection site reactions, and immediate reactions suggestive of IgE-mediated mechanisms are discussed. Desensitization can be considered for reactions suggestive of IgE-mediated mechanisms, but allergists/immunologists should be involved in managing these patients.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biologic agents; Delayed reaction; Drug desensitization; Infusion reaction; Monoclonal antibodies; Omalizumab; Rituximab

Mesh:

Substances:

Year:  2017        PMID: 28366484     DOI: 10.1016/j.iac.2017.01.012

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  13 in total

1.  Postmarketing Safety-Related Regulatory Actions for New Therapeutic Biologics Approved in the United States 2002-2014: Similarities and Differences With New Molecular Entities.

Authors:  Ilynn Bulatao; Ellen Pinnow; Brendan Day; Sanae Cherkaoui; Manish Kalaria; Sonja Brajovic; Gerald Dal Pan
Journal:  Clin Pharmacol Ther       Date:  2020-09-08       Impact factor: 6.903

2.  Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis.

Authors:  Yan-Hua Zheng; Li Xu; Chun Cao; Juan Feng; Hai-Long Tang; Mi-Mi Shu; Guang-Xun Gao; Xie-Qun Chen
Journal:  Onco Targets Ther       Date:  2019-04-11       Impact factor: 4.147

Review 3.  Case Reports of DRESS Syndrome and Symptoms Consistent with DRESS Syndrome Following Treatment with Recently Marketed Monoclonal Antibodies.

Authors:  James C Di Palma-Grisi; Kesav Vijayagopal; Muhammad A Muslimani
Journal:  Autoimmune Dis       Date:  2019-06-09

Review 4.  Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.

Authors:  Carmen F Nobre; Matthew J Newman; Anne DeLisa; Pauline Newman
Journal:  Cancer Chemother Pharmacol       Date:  2019-05-27       Impact factor: 3.333

5.  Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review.

Authors:  Dominik Samotij; Adam Reich
Journal:  Biomed Res Int       Date:  2019-07-18       Impact factor: 3.411

Review 6.  Gene Therapy for Liver Cancers: Current Status from Basic to Clinics.

Authors:  Kenya Kamimura; Takeshi Yokoo; Hiroyuki Abe; Shuji Terai
Journal:  Cancers (Basel)       Date:  2019-11-25       Impact factor: 6.639

7.  Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management.

Authors:  Miriam Hobbs; Amie Fonder; Yi L Hwa
Journal:  J Adv Pract Oncol       Date:  2020-05-01

8.  In Vivo Fluorescence Imaging of Passive Inflammation Site Accumulation of Liposomes via Intravenous Administration Focused on Their Surface Charge and PEG Modification.

Authors:  Hisako Ibaraki; Akihiro Takeda; Naoki Arima; Naruhiro Hatakeyama; Yuuki Takashima; Yasuo Seta; Takanori Kanazawa
Journal:  Pharmaceutics       Date:  2021-01-14       Impact factor: 6.321

Review 9.  Drug allergy.

Authors:  Richard Warrington; Fanny Silviu-Dan; Tiffany Wong
Journal:  Allergy Asthma Clin Immunol       Date:  2018-09-12       Impact factor: 3.406

Review 10.  Roadmap and strategy for overcoming infusion reactions to nanomedicines.

Authors:  Janos Szebeni; Dmitri Simberg; África González-Fernández; Yechezkel Barenholz; Marina A Dobrovolskaia
Journal:  Nat Nanotechnol       Date:  2018-10-22       Impact factor: 39.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.